Enterprise 2 stent outcomes in hyperacute ischemic stroke with intracranial artery stenosis

Recent studies have indicated that intracranial stenting may positively affect the prognosis of patients with ischemic stroke. However, most patients included in these studies were in the hyperacute stage of ischemic stroke. Moreover, few studies with limited numbers of patients have examined the factors affecting the prognosis of patients with hyperacute stroke. Therefore, this study aimed to evaluate patient prognosis and factors associated with emergent intracranial stenting with the Enterprise 2 stent in patients with hyperacute ischemic stroke secondary to sudden intracranial artery occlusion.

Patients with hyperacute ischemic stroke admitted to a single institution between January 2017 and December 2019 were retrospectively analyzed. Sixty-five patients with major intracranial artery occlusion associated with neurological deficits were selected. All patients underwent emergent intracranial stenting of the index artery after mechanical thrombectomy. We investigated the following composite outcomes: death, vessel reocclusion, and stroke recurrence.

Participants' mean age was 69.9 ± 12.3 years, and 57.6% were males. The middle cerebral artery was the most occluded (61.0%). The mean follow-up period was 8.4 ± 6.4 months; four patients developed arterial reocclusion. At the end of the follow-up period, the mean modified Rankin scale score was 4 and composite outcomes were observed in 14 patients.

Emergent intracranial stenting using the Enterprise 2 stent resulted in a relatively favorable prognosis in patients with acute ischemic stroke. In addition, smoking status and the National Institutes of Health Stroke Scale score at admission were significant prognostic factors.